文献速递类风湿关节炎血管炎

血清胆固醇负载能力变化与类风湿关节炎患者冠状动脉粥样硬化进展相关

Changes in serum cholesterol loading capacity are linked to coronary atherosclerosis progression in rheumatoid arthritis.
PubMed 文献 · RMD Open · 2024-12-24

前瞻性观察性队列研究纳入100例无心血管疾病的类风湿关节炎患者,基线及6.9±0.4年后行冠状动脉CT血管造影,用荧光法测定血清胆固醇负载能力(CLC)。校正动脉粥样硬化性心血管疾病风险评分、基线斑块等协变量后,CLC变化(每增加1个标准差)与非钙化斑块、完全钙化斑块、冠状动脉钙化(CAC)及新发广泛或阻塞性病变进展风险升高相关;泼尼松暴露不利于该关系,生物制剂和他汀则有利。

要点

  • CLC变化(每增加1个标准差)与非钙化斑块进展相关(OR 2.55,95%CI 1.22至5.35)。
  • CLC变化与完全钙化斑块进展相关(OR 3.10,95%CI 1.67至5.76),与CAC进展相关(OR 1.80,95%CI 1.18至2.74)。
  • CLC变化与新发广泛或阻塞性病变相关(OR 2.43,95%CI 1.11至5.34);泼尼松暴露不利、生物制剂和他汀有利(交互作用P值均≤0.048)。

核心结论

  • CLC变化与类风湿关节炎患者动脉粥样硬化进展呈剂量依赖性相关,包括富含脂质的非钙化斑块及心血管风险最高的广泛或阻塞性病变。

研究设计与样本

  • 前瞻性观察性队列研究,纳入100例基线无心血管疾病的类风湿关节炎患者,基线及6.9±0.4年后行冠状动脉CT血管造影评估动脉粥样硬化(非钙化、部分钙化或完全钙化斑块及CAC评分)。
  • 血清CLC在人THP-1单核细胞来源巨噬细胞上以荧光法测定。
  • 存在≥5个斑块定义为广泛病变,引起>50%狭窄的病变定义为阻塞性病变。

主要发现

  • CLC平均变化(随访CLC减基线CLC)为1.54(标准差3.69)μg胆固醇/mg蛋白。
  • 在校正动脉粥样硬化性心血管疾病风险评分、基线斑块及其他相关协变量的模型中,CLC变化(每增加1个标准差)与非钙化斑块进展风险升高相关(OR 2.55,95%CI 1.22至5.35)。
  • CLC变化与完全钙化斑块进展风险升高相关(OR 3.10,95%CI 1.67至5.76)。
  • CLC变化与CAC进展风险升高相关(OR 1.80,95%CI 1.18至2.74)。
  • CLC变化与新发广泛或阻塞性病变风险升高相关(OR 2.43,95%CI 1.11至5.34)。

关键数值与推荐

  • 泼尼松暴露对CLC变化与动脉粥样硬化进展的关系有不利影响,生物制剂和他汀有有利影响(交互作用P值均≤0.048)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Excess cholesterol loading on arterial macrophages is linked to foam cell formation, atherosclerosis and cardiovascular risk in rheumatoid arthritis (RA). However, the effect of changes in cholesterol loading on coronary plaque trajectory and the impact of RA therapies on this relationship are unknown. We investigated the association between variations in cholesterol loading capacity (CLC) over time and atherosclerosis progression. METHODS: In a prospective observational cohort study, coronary CT angiography evaluated atherosclerosis (non-calcified, partially calcified or fully calcified plaques and coronary artery calcium (CAC) score) in 100 patients with RA without cardiovascular disease at baseline and 6.9±0.4 years later. The presence of ≥5 plaques and lesions rendering >50% stenosis was considered an extensive and obstructive disease, respectively. Serum CLC was measured on human THP-1 monocyte-derived macrophages with a fluorometric assay. RESULTS: Mean CLC change (follow-up CLC-baseline CLC) was 1.54 (SD 3.69) μg cholesterol/mg protein. In models adjusting for atherosclerotic cardiovascular disease risk score, baseline plaque and other relevant covariates, CLC change (per SD unit increase) is associated with a higher likelihood of progression of non-calcified (OR 2.55, 95% CI 1.22 to 5.35), fully calcified plaque (OR 3.10, 95% CI 1.67 to 5.76), CAC (OR 1.80, 95% CI 1.18 to 2.74) and new extensive or obstructive disease (OR 2.43, 95% CI 1.11 to 5.34). Exposure to prednisone unfavourably influenced, while biologics and statins favourably affected the relationship between CLC change and atherosclerosis progression (all p-for-interactions ≤0.048). CONCLUSION: CLC change is associated with atherosclerosis progression in a dose-dependent manner, including lipid-rich non-calcified plaques and extensive or obstructive disease that yield the greatest cardiovascular risk.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Karpouzas GA, Papotti B, Ormseth SR, et al. Changes in serum cholesterol loading capacity are linked to coronary atherosclerosis progression in rheumatoid arthritis. RMD Open. 2024. PMID: 39719397. doi:10.1136/rmdopen-2024-004991

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。